ASCO 2023 | Post adjuvant PD-1 analysis of fianlimab and cemiplimab in melanoma

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses findings from a Phase I trial (NCT03005782) of fianlimab and cemiplimab, an anti-LAG-3 and PD-1 antibody respectively, in patients with advanced melanoma. 98 patients exposed to prior PD-1 inhibitors were enrolled, and addition of fianlimab resulted in improved survival with no additional safety concerns. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.